Bayer to acquire Asklepios Bio from TPG Capital, Columbus Venture and Vida Ventures for c. $4bn.

Bayer, a global enterprise with competencies in the life science fields of health care and nutrition, agreed to acquire Asklepios Bio, an unlisted US biotech firm, from TPG Capital, Columbus Venture and Vida Ventures for c. $4bn. Closing of the transaction is contingent on customary closing conditions, including receipt of the required regulatory approvals, and is expected to take place during the fourth quarter of 2020. “As part of our strategy, we are building new therapeutic platforms including cell and gene therapies. As an emerging leader in the rapidly advancing field of gene therapies, the expertise and portfolio of AskBio supports us in establishing highly innovative treatment options for patients and further strengthens our portfolio. We want to help patients whose medical needs are not yet met by today’s treatment options and we are looking forward to work together with the team at AskBio,” Stefan Oelrich, Bayer Member of the Board of Management and Bayer Pharmaceuticals Division President.